Advertisement

Topics

Latest "Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal" News Stories

18:34 EDT 23rd October 2018 | BioPortfolio

Here are the most relevant search results for "Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal" found in our extensive news archives from over 250 global news sources.

More Information about Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal for you to read. Along with our medical data and news we also list Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal Companies for you to search.

Showing "Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal" News Articles 1–25 of 8,200+

Tuesday 23rd October 2018

SpineGuard SA ALSGD Financial and Strategic SWOT Analysis Review [Report Updated: 28092018] Prices from USD $300

SummarySpineGuard SA SpineGuard is a medical device company that designs, develops and markets spine surgery products. The company offers PediGuard, a device that detects possible vertebral cortex perforation during pedicle preparation. It offers screw placement and alerts to surgeon prior that breach by analyzing the electrical conductivity of the surrounding tissues in real time. SpineGuard also...


Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma

Post-hoc analysis of EF-14 phase 3 pivotal trial demonstrated that power loss density and electric field intensity were associated with improved overall survival, independent of compliance This is the first analysis to quantify the delivered dose of Tumor Treating Fields, defined as a function of both power loss density and monthly usage of therap...

SpineGuard SA ALSGD Product Pipeline Analysis, 2018 Update [Report Updated: 10102018] Prices from USD $750

SummarySpineGuard SA SpineGuard is a medical device company that designs, develops and markets spine surgery products. The company offers PediGuard, a device that detects possible vertebral cortex perforation during pedicle preparation. It provides offers screw placement and alerts to surgeon prior that breach by analyzing the electrical conductivity of the surrounding tissues in real time. SpineG...


REVLIMID® (lenalidomide) Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma

Celgene Corporation (NASDAQ: CELG) today announced results from an open-label phase II/III National Clinical Trials Network (NCTN) study led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. REVLIMID® (lenalidomide) was provided by Celgene under a clinical trials agreem...

LeMaitre Vascular Inc LMAT Medical Equipment Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryLeMaitre Vascular Inc LeMaitre Vascular provides medical devices and services for the treatment of peripheral vascular diseases. The company develops, manufactures, and markets disposable and implantable devices that vascular surgeons use in arteries and veins outside the heart in open vascular surgeries and minimally invasive procedures. Its product portfolio includes angioscopes, balloon ...

Mati Therapeutics Expands Intellectual Property Portfolio with 114 Patents Issued

Portfolio Covers 19 Patent Families Across Major Markets Mati Therapeutics Inc. (“Mati”) announced that its international patent portfolio has grown to 114 issued patents, including recently granted U.S. Patent No. 9,849,082, titled “Nasolacrimal Drainage System Implants for Drug Therapy." This patent, which will not expire until 2027, ...

Ryan Murphy and David Miller Donate $10 Million to Children’s Hospital Los Angeles

The couple’s son received lifesaving care at CHLA, which will name a floor in his honor On behalf of the Ford Theodore Miller Murphy Family, Emmy-Award winning writer, producer and director Ryan Murphy and his husband, photographer David Miller, have made a landmark $10 million gift to Children’s Hospital Los Angeles (CHLA). In honor of this incred...

OncLive® Records the Highest Number of Same-Day Visitors in Website’s History

OncLive®’s coverage of ESMO 2018 drives spike in web traffic OncLive®, the leading digital provider of resources and information to oncology professionals, reached a landmark 31,849-page views on Monday, Oct. 22, a single-day record for the website. “We are thrilled to reach a new single-day web traffic record. This is a major milestone ...

Scientia Vascular Appoints Rick Randall to Its Board

Scientia Vascular, LLC, a commercial-stage medical device company with patented, proprietary, and FDA-approved vascular access technology, recently appointed Rick Randall as executive director to its board. Rick has served as CEO for both private and publicly traded companies such as Target Therapeutics, Innovasive Devices, TranS1 and OMNIlife Science. Mr....

Cyclin Dependent Kinase 1 p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23 Pipeline Review, H2 2018 [Report Updated: 21082018] Prices from USD $3500

Cyclin Dependent Kinase 1 p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23 Pipeline Review, H2 2018SummaryAccording to the recently published report 'Cyclin Dependent Kinase 1 Pipeline Review, H2 2018'; Cyclin Dependent Kinase 1 p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Prot...

Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains

Infant-type HRB may eliminate potentially harmful food-derived opioid peptides in infants’ intestines Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting good health outcomes. The results of a new ...

MedX Health Announces That Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany Has Joined Its Medical Advisory Board

MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin. “The addition of Dr. Stockfleth t...

Zafgen Inc ZFGN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryZafgen Inc Zafgen is a clinicalstage biopharmaceutical company that develops transformative therapies for patients affected by a range of metabolic diseases. Its pipeline product portfolio includes ZGN1061, a small molecule MetAP2 inhibitor being developed for patients with type 2 diabetes; ZGN1258 is designed to change the way the body metabolizes fat, reduce fat mass, and decrease hyperph...

Pulmatrix Inc PULM Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryPulmatrix Inc Pulmatrix, formerly Ruthigen Inc is a clinical stage biopharmaceutical company that develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline product using its proprietary inhaled small particles easily respirable and emitted dry powder delivery technologies. Its pipeline product includ...

OncoMed Pharmaceuticals Inc OMED Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryOncoMed Pharmaceuticals Inc OncoMed is a clinicalstage biopharmaceutical company focused on discovery and development of novel immunooncology IO therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, GitrlFC Trimer, and antiTIGIT. OncoMed's research platform enables to build a portfolio of active therapeutic compounds that target bio...

NovaDigm Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryNovaDigm Therapeutics Inc NovaDigm is a developer of immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial diseases. The company's products include NDV3 vaccines, vaccine clinical supplies, ALS3 vaccines, bacterial and fungal vaccine antigens, fungal and bacterial pathogens vaccines, and vaginal and bloodstream infections treatment vaccines. It also prov...

Sierra Oncology Inc SRRA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummarySierra Oncology Inc Sierra Oncology, formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company's product candidate includes SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It also develops SRA141, a small molecule inhibitor of the cel...

Mersana Therapeutics Inc MRSN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryMersana Therapeutics Inc Mersana formerly Nanopharma Corp is a clinicalstage biopharmaceutical company that offers antibody drug conjugate to improve patients' lives. The company offers pipeline product XMT1522, for HER2 targeted therapies based on its Dolaflexin platform. It utilizes Fleximer antibody drug conjugation ADC platform, Dolaflexin to design ADC's with drugtoantibody ratios. Mer...

Vascular Biogenics Ltd VBLT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryVascular Biogenics Ltd VBL is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company's product pipeline includes VB111. VBL's product VB111 is an antiangiogenic agent for the specific inhibition of tumor vascular growth for cancer therapy. The company also administers treatment for solid tumor indications, with clinical trials in ...

Stemline Therapeutics Inc STML Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryStemline Therapeutics Inc Stemline is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pipeline comprises of SL401, SL701, SL801, SL501 and SL101. Stemline's SL401 is a targeted therapy direct...

Romark Laboratories LC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryRomark Laboratories LC Romark Laboratories is a pharmaceutical company that discovers, develops and commercializes small molecules for the treatment of infectious diseases and cancers. The company develops Nitazoxanide, an oral suspension and tablets used for the treatment of intestinal parasitic infections caused by the intestinal protozoa cryptosporidium parvum, giardia intestinalis, enta...

Presidio Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryPresidio Pharmaceuticals Inc Presidio Pharmaceuticals is a clinicalstage pharmaceutical company that discovers, develops, and supplies smallmolecule antiviral therapeutics. The company's products include HCV NS5A, protease inhibitor, ravidasvir hydrochloride, NS5B proteins, lead pangenotypic HCV NS5A inhibitor, faldaprevir and nonnucleoside inhibitor. Its lead pangenotypic HCV NS5A inhibito...

Synthetic Biologics Inc SYN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummarySynthetic Biologics Inc Synthetic Biologics, formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company's pipeline products include SYN004 and SYN010. Its SYN010 is a proprietary, modifiedrelease formulation which is intended to treat rritable bowel syndrome with constipation. Synthetic Biologics' SYN004 is an oral prophyl...

Oncolys BioPharma Inc 4588 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryOncolys BioPharma Inc Oncolys is a biotechnology company that discovers and develops treatments for cancer and infectious diseases. The company import and export products including drugs and medicines, oncolytic viruses, pharmaceutical pipeline products and tumor diagnostic agents, among others. Its pharmaceutical pipeline products include OBP301, OBPAI001, OBP801, OBP601, and OBPAI002, amo...

Tragara Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryTragara Pharmaceuticals Inc Tragara Pharmaceuticals is a pharmaceutical company focused on the clinical and commercial development of its proprietary medicines for the treatment of various cancers. Its lead product candidate TG02, an oral multikinase inhibitor facilitates antitumor activity, resulting to the depletion of the key cancer cell survival protein, cMyc. Overexpression of the MYC ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks